文献速递肝病消化道肿瘤与早癌

晚期肝细胞癌抗PD1治疗应答的分子标志物

Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma.
PubMed 文献 · Gastroenterology · 2022-09-12

本研究从13个中心获取111例晚期肝细胞癌患者的肿瘤样本,在系统治疗前进行分子与免疫分析。全基因组表达数据显示,一线应答者干扰素-γ信号及MHC II类抗原呈递上调,据此构建的11基因签名(IFNAP)可预测一线抗PD1治疗的应答与生存,并在其他实体瘤中验证,但该签名无法预测TKI治疗患者的应答。

要点

  • 一线抗PD1应答者干扰素-γ信号与MHC II类抗原呈递上调。
  • 11基因签名IFNAP可预测一线抗PD1治疗的应答与生存。
  • 该签名不能预测TKI治疗患者的应答,免疫治疗前需新鲜活检。

核心结论

  • 干扰素信号与MHC相关基因是肝细胞癌应答抗PD1的关键分子特征。
  • 新型11基因签名可预测一线晚期肝细胞癌的应答,但对TKI预处理患者不适用。
  • 结果需在前瞻性研究中确认,并强调免疫治疗前活检以识别应答生物标志物的必要性。

研究设计与样本

  • 研究从13个中心获取111例晚期肝细胞癌患者在系统治疗前的肿瘤样本。
  • 对83例样本进行全基因组表达数据分析与免疫解卷积。
  • 对72例样本进行突变分析,并进行组织学评估,终点为客观应答。

主要发现

  • 83例有转录组数据的患者中,28例接受一线治疗,55例在TKI治疗后接受二线或三线治疗。
  • 一线应答者显示干扰素-γ信号和MHC II类相关抗原呈递上调。
  • 11基因签名IFNAP在独立晚期肝细胞癌队列及>240例其他实体瘤患者中验证,可预测应答与生存。
  • 同一签名无法预测一线TKI治疗患者存档组织的应答。

临床怎么用

  • 作者认为,免疫治疗前需进行活检以识别应答生物标志物。

局限性

  • 原文指出结果必须在前瞻性研究中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Single-agent anti-PD1 checkpoint inhibitors convey outstanding clinical benefits in a small fraction (∼20%) of patients with advanced hepatocellular carcinoma (aHCC) but the molecular mechanisms determining response are unknown. To fill this gap, we herein analyze the molecular and immune traits of aHCC in patients treated with anti-PD1. METHODS: Overall, 111 tumor samples from patients with aHCC were obtained from 13 centers before systemic therapies. We performed molecular analysis and immune deconvolution using whole-genome expression data (n = 83), mutational analysis (n = 72), and histologic evaluation with an endpoint of objective response. RESULTS: Among 83 patients with transcriptomic data, 28 were treated in frontline, whereas 55 patients were treated after tyrosine kinase inhibitors (TKI) either in second or third line. Responders treated in frontline showed upregulated interferon-γ signaling and major histocompatibility complex II-related antigen presentation. We generated an 11-gene signature (IFNAP), capturing these molecular features, which predicts response and survival in patients treated with anti-PD1 in frontline. The signature was validated in a separate cohort of aHCC and >240 patients with other solid cancer types where it also predicted response and survival. Of note, the same signature was unable to predict response in archival tissue of patients treated with frontline TKIs, highlighting the need for fresh biopsies before immunotherapy. CONCLUSION: Interferon signaling and major histocompatibility complex-related genes are key molecular features of HCCs responding to anti-PD1. A novel 11-gene signature predicts response in frontline aHCC, but not in patients pretreated with TKIs. These results must be confirmed in prospective studies and highlights the need for biopsies before immunotherapy to identify biomarkers of response.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Haber PK, Castet F, Torres-Martin M, et al. Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma. Gastroenterology. 2022. PMID: 36108710. doi:10.1053/j.gastro.2022.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。